Program
Autologous HLA-A*02:01-restricted Mutant NPM1-directed TCR-expressing T-lymphocytes BSB-2002
Also written as “SOC+ BSB-2002” and “SOC+BSB-2002”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by BlueSphere Bio.
Furthest: phase 1, since Apr 21, 20261 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BlueSphere Bio | 10 open or running | phase 1since Apr 21, 2026 | Apr 21, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 21, 2026First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT07566585 · United States
TargetBeta
NPM1 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A*02:01-restricted mutated nucleophosmin (NPM1; nucleolar phosphoprotein B23), ”NCIt, by rule
Other programs on NPM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07566585Leukemia, Myeloid, Acute · United States | 1 | Withdrawn | Sep 8, 2026 | 0 |
How it is read
Names in the registry
- “SOC+ BSB-2002”, 1 entry
- “SOC+BSB-2002”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.